These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 38353050

  • 1. Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study.
    Chen L, Jin T, Fang Y, Wu G, Yuan Y.
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1073-1081. PubMed ID: 38353050
    [Abstract] [Full Text] [Related]

  • 2. Effect of Marital Status on the Survival of Patients With Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Study.
    Wang S, Chen L, Chen D, Chao J, Shao Y, Tang K, Chen W.
    Cancer Control; 2021 Jun; 28():10732748211066309. PubMed ID: 34910613
    [Abstract] [Full Text] [Related]

  • 3. Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis.
    Chen Y, Jin M, Shao Y, Xu G.
    Dis Markers; 2019 Jun; 2019():4659048. PubMed ID: 31781301
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
    Zhu Z, Wang Y, Li F, Gao J, Han B, Wang R, Xue Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb 25; 22(2):149-155. PubMed ID: 30799537
    [Abstract] [Full Text] [Related]

  • 5. Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: A comparative analysis according to Siewert classification in a Japanese cohort.
    Urabe M, Ushiku T, Shinozaki-Ushiku A, Iwasaki A, Yamazawa S, Yamashita H, Seto Y, Fukayama M.
    Cancer Med; 2018 Oct 25; 7(10):5145-5154. PubMed ID: 30239168
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Prognostic Abilities Among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma.
    Urabe M, Yamashita H, Watanabe T, Seto Y.
    World J Surg; 2018 Jan 25; 42(1):185-194. PubMed ID: 28741195
    [Abstract] [Full Text] [Related]

  • 7. Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry.
    Zhu K, Xu Y, Fu J, Mohamud FA, Duan Z, Tan S, Zhao Z, Chen P, Zong L.
    Dis Markers; 2019 Jan 25; 2019():9637972. PubMed ID: 31976023
    [Abstract] [Full Text] [Related]

  • 8. Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.
    Chen L, Tang K, Wang S, Chen D, Ding K.
    Cancer Control; 2021 Jan 25; 28():10732748211026668. PubMed ID: 34155922
    [Abstract] [Full Text] [Related]

  • 9. Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.
    Chen J, Jia X, Chen H, Cai J, Chen L.
    Cancer Control; 2023 Jan 25; 30():10732748231208313. PubMed ID: 37851478
    [Abstract] [Full Text] [Related]

  • 10. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.
    Xiao JW, Liu ZL, Ye PC, Luo YJ, Fu ZM, Zou Q, Wei SJ.
    World J Gastroenterol; 2015 Sep 14; 21(34):9999-10007. PubMed ID: 26379405
    [Abstract] [Full Text] [Related]

  • 11. Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option.
    Hu C, Zhu HT, Xu ZY, Yu JF, Du YA, Huang L, Yu PF, Wang LJ, Cheng XD.
    J Int Med Res; 2019 Jan 14; 47(1):398-410. PubMed ID: 30296865
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
    Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E.
    Anticancer Res; 2017 Jun 14; 37(6):3129-3135. PubMed ID: 28551654
    [Abstract] [Full Text] [Related]

  • 13. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
    Hu X, Wu L, Liu B, Chen K.
    Front Immunol; 2021 Jun 14; 12():651056. PubMed ID: 34122409
    [Abstract] [Full Text] [Related]

  • 14. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study.
    Chen K, Deng X, Yang Z, Yu D, Zhang X, Li W, Xie D, He Z, Cheng D.
    Expert Rev Gastroenterol Hepatol; 2020 Jun 14; 14(6):491-497. PubMed ID: 32324423
    [Abstract] [Full Text] [Related]

  • 15. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?
    Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A.
    Gastric Cancer; 2018 Mar 14; 21(2):303-314. PubMed ID: 28685209
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the 8th UICC staging system for esophageal and gastric cancers in Siewert type II junctional adenocarcinomas.
    Karstens KF, Ghadban T, Sawez S, Konczalla L, Woestemeier A, Bachmann K, Uzunoglu FG, Tachezy M, Vettorazzi E, Izbicki JR, Reeh M.
    Eur J Surg Oncol; 2020 Apr 14; 46(4 Pt A):638-643. PubMed ID: 31879051
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
    Schmidt SC, Schlechtweg N, Veltzke-Schlieker W, Thuss-Patience P, Pratschke J, Neuhaus P, Schumacher G.
    Zentralbl Chir; 2009 Sep 14; 134(5):455-61. PubMed ID: 19757346
    [Abstract] [Full Text] [Related]

  • 19. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.
    Sisic L, Strowitzki MJ, Blank S, Nienhueser H, Dorr S, Haag GM, Jäger D, Ott K, Büchler MW, Ulrich A, Schmidt T.
    Gastric Cancer; 2018 May 14; 21(3):552-568. PubMed ID: 28741059
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction.
    Sun L, Chen F, Shi W, Qi L, Zhao Z, Zhang J.
    Diagn Pathol; 2014 Jul 16; 9():125. PubMed ID: 25029906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.